Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
ImmuneBiotech looks to IPO in 2021-2022
September 24, 2020
ImmuneBiotech, a Lund-based lactic acid bacteria company, has received an approved patent in the USA for its dietary supplement Gutmagnific. The company, which is a spin-off from Lund University, also revealed that they are active in a financing round to raise SEK 13m. CEO Shahram Lavasani also looks to list the company on Nasdaq Firsth North in 2021-2022.
ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: